Huanglian Jiedu Decoction Inhibits LPS-induced Neuroinflammation and Attenuates the  Activation of NLRP3 Inflammasome in  BV2 Cells-Reference-Cited by-同舟云学术

Huanglian Jiedu Decoction Inhibits LPS-induced Neuroinflammation and Attenuates the  Activation of NLRP3 Inflammasome in  BV2 Cells

Published:2024-05-09 Issue: Volume: Page:
ISSN:0973-1296
Container-title:Pharmacognosy Magazine
language:en
Short-container-title:Pharmacognosy Magazine

Author:

Wang Junli¹,Wang Rui²^ORCID,Du Yaming²,Xu Xinzi²,Liu Xin¹,Shao Wei¹^ORCID,Chen Guohua¹²

Affiliation:

1. Department of Neurology, Wuhan No. 1 Hospital, Wuhan, Hubei, China

2. College of Clinical Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, China

Abstract

Background: Huanglian Jiedu decoction (HLJDD) is a classical herbal formula for treating inflammatory diseases with Traditional Chinese Medicine (TCM). However, the impacts of HLJDD on neuroinflammation and the precise mechanisms involved remain poorly understood. Purpose: In the present study, HLJDD was found to inhibit lipopolysaccharide (LPS) induced neuroinflammatory responses in BV2 microglia via regulating NLRP3 inflammasome activation. Methods: Anti-inflammatory activity was evaluated with ELISA assay and the polarization changes were observed using immunofluorescent staining. The levels of NLRP3 inflammasome activation were determined using qPCR and Western blotting. Results: The administration of HLJDD successfully countered LPS-induced neuroinflammatory responses by attenuating microglial activation and fostering a phenotypic conversion from the pro-inflammatory M1 to the anti-inflammatory M2. . Additionally, HLJDD treatment demonstrated inhibition of NLRP3 inflammasome activation. Conclusion: The findings of the present study may provide insights into how HLJDD could be a therapeutic drug for neuroinflammatory diseases associated with regulating NLRP3 inflammasome and microglial activation.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/09731296241244575

Reference30 articles.

1. Cai Y., Wen J., Ma S., Mai Z., Zhan Q., Wang Y., Zhang Y., Chen H., Li H., Wu W., Li R. & Luo C. (2021). Huang-Lian-Jie-Du decoction attenuates atherosclerosis and increases plaque stability in high-fat diet-induced ApoE(−/−) mice by inhibiting M1 macrophage polarization and promoting M2 macrophage polarization. Frontiers in Physiology, 12, 666449. https://doi.org/10.3389/fphys.2021.666449

2. Chen J., Chen S., Chen J., Shen B., Jiang Z. & Xu Y. (2021). Study on the molecular basis of Huanglian Jiedu decoction against atopic dermatitis integrating chemistry, biochemistry, and metabolomics strategies. Frontiers in Pharmacology, 12, 770524. https://doi.org/10.3389/fphar.2021.770524

3. Colonna M. & Butovsky O. (2017). Microglia function in the central nervous system during health and neurodegeneration. Annual Review of Immunology, 35, 441–468. https://doi.org/10.1146/annurev-immunol-051116-052358

4. Cunha C., Gomes C., Vaz A. R. & Brites D. (2016). Exploring new inflammatory biomarkers and pathways during LPS-induced M1 polarization. Mediators of Inflammation, 2016, 6986175. https://doi.org/10.1155/2016/6986175

5. Gu X., Zhou J., Zhou Y., Wang H., Si N., Ren W., Zhao W., Fan X., Gao W., Wei X., Yang J., Bian B. & Zhao H. (2021). Huanglian Jiedu decoction remodels the periphery microenvironment to inhibit Alzheimer’s disease progression based on the “brain-gut” axis through multiple integrated omics. Alzheimer’s Research and Therapy, 13(1), 44. https://doi.org/10.1186/s13195-021-00779-7